Merion Care

Merion Care is a clinical-stage biopharmaceutical company specializing in the development of advanced drug delivery technologies to enhance the efficacy and patient adherence of existing therapeutics. The company utilizes its proprietary M-Oral platform to convert injectable biologics and poorly soluble drugs into oral formulations, and its M-Sustain platform for long-acting injectable controlled release. Their primary focus areas include metabolic diseases, such as diabetes and obesity, and pain management. Merion Care's lead candidate is an oral GLP-1 receptor agonist currently in mid-stage clinical development. The company leverages the 505(b)(2) regulatory pathway to streamline the approval process for its innovative reformulations.